肝与肾有机阳离子转运体对西咪替丁-二甲双胍临床药代相互作用定量贡献的研究
PBPK模型预测西咪替丁主要抑制肝OCT1,对肾OCT2抑制作用较小;西咪替丁暴露后潜在OCT2生物标志物肾清除率不变,支持肾OCT2在该相互作用中作用甚微。
要点
- 西咪替丁使二甲双胍血浆暴露增加24%(p<0.05),肾清除率下降8%(p=0.005)。
- PBPK模型预测西咪替丁主要抑制肝OCT1,对肾OCT2抑制较小。
- 潜在OCT2生物标志物肾清除率不变,提示肾OCT2作用有限。
核心结论
- 西咪替丁-二甲双胍相互作用主要涉及抑制肝OCT1,肾OCT2贡献较小。
研究设计与样本
- 研究还开发了PBPK模型并评估血浆和尿液中潜在OCT生物标志物。
主要发现
- 与基线相比,西咪替丁存在时二甲双胍全身血浆暴露增加24%(p<0.05)。
- 二甲双胍肾清除率下降8%(p=0.005)。
- OCT1和OCT2遗传变异中度影响相互作用的显著性和幅度。
- PBPK模型预测西咪替丁主要抑制肝OCT1,对肾OCT2抑制程度较小。
- 西咪替丁暴露后潜在OCT2生物标志物的肾清除率不变。
临床怎么用
- 临床联用西咪替丁与二甲双胍时,应关注肝OCT1介导的药物相互作用可能增加二甲双胍全身暴露。
- 肾OCT2对该相互作用的贡献有限,提示肾功能相关的剂量调整可能不是主要考量。
局限性
- 原文未报告具体遗传变异类型及影响程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The widely prescribed oral anti-diabetic drug metformin is eliminated unchanged in the urine primarily through active tubular secretion. This process is mediated by organic cation transporter 2 (OCT2), an uptake transporter expressed on the basolateral membrane of renal proximal tubule cells. Metformin uptake into the liver, the site of action, is mediated by organic cation transporter 1 (OCT1), which is expressed on the sinusoidal membrane of hepatocytes. Sixteen healthy adults participated in a clinical pharmacokinetic drug-drug interaction study in which they were orally administered metformin (50 mg) as a dual OCT1/2 substrate alone (baseline) and with cimetidine (400 mg) as an OCT inhibitor. Relative to baseline, metformin systemic plasma exposure increased by 24% (p < 0.05) in the presence of cimetidine, which was accompanied by a disproportional decrease (8%) in metformin renal clearance (p = 0.005). Genetic variants of OCT1 and OCT2 moderately impacted the significance and magnitude of the interaction. Collectively, we hypothesized that the cimetidine-metformin interaction involves inhibition of hepatic OCT1 as well as renal OCT2. We tested this hypothesis by developing a physiologically based pharmacokinetic (PBPK) model and assessing potential OCT biomarkers in plasma and urine to gain mechanistic insight into the transporters involved in this interaction. The PBPK model predicted that cimetidine primarily inhibits hepatic OCT1 and, to a lesser extent, renal OCT2. The unchanged renal clearance of potential OCT2 biomarkers following cimetidine exposure supports a minimal role for renal OCT2 in this interaction.
引用
- Ailabouni AS, Singh DK, Thakur A, et al. Quantitative Contributions of Hepatic and Renal Organic Cation Transporters to the Clinical Pharmacokinetic Cimetidine-Metformin Interaction. Clin Pharmacol Ther. 2025. PMID: 40098288. doi:10.1002/cpt.3639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。